Targeting the JAK-STAT pathway in autoimmune diseases and cancers: A focus on molecular mechanisms and therapeutic potential
- 1 November 2021
- journal article
- review article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 193, 114760
Abstract
No abstract availableKeywords
Funding Information
- Chang Gung Memorial Hospital (CMRPG1H0101)
- Ministry of Science and Technology, Taiwan (108-2314-B-281-003-MY3, 109-2320-B-182A-016-MY3, 110-2314-B-281-013-, MOST 110-2314-B-182A-127-MY3)
- Chang Gung Memorial Hospital
This publication has 112 references indexed in Scilit:
- Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinomaGenome Research, 2013
- JAK/STAT signaling in hematological malignanciesOncogene, 2012
- Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell–stimulated T cells yet preserves immunity to recall antigenBlood, 2011
- STAT5 Activation Is Critical for the Transformation Mediated by Myeloproliferative Disorder-associated JAK2 V617F MutantJournal of Biological Chemistry, 2010
- A JAK2 Interdomain Linker Relays Epo Receptor Engagement Signals to Kinase ActivationJournal of Biological Chemistry, 2009
- Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cellsNature Medicine, 2009
- JAK mutations in high-risk childhood acute lymphoblastic leukemiaProceedings of the National Academy of Sciences, 2009
- Acetylation and activation of STAT3 mediated by nuclear translocation of CD44Journal of Cell Biology, 2009
- Role of JAK2 in the pathogenesis and therapy of myeloproliferative disordersNature Reviews Cancer, 2007
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005